Alaunos Pharmaceuticals

Alaunos Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation adoptive TCR-T cell therapies for the treatment of solid tumors. The company utilizes its proprietary non-viral Sleeping Beauty gene transfer platform to engineer T-cells that target specific neoantigens, including mutations in KRAS, TP53, and EGFR. This approach aims to provide a more cost-effective and scalable alternative to traditional viral-based cell therapies. In late 2023, the company underwent a significant strategic restructuring, pausing its lead TCR-T Library Phase 1/2 trial to conserve capital and explore strategic alternatives. Alaunos is headquartered in Houston, Texas, and maintains a long-standing research collaboration with the MD Anderson Cancer Center.